Lilly to shell out billions of dollars to acquire Loxo Oncology

7 January 2019
lilly-location-big-1

US pharma major Eli Lilly (NYSE: LLY) today announced the second multi-billion dollar acquisition of the New Year, saying it had reached a definitive agreement to acquire Loxo Oncology (Nasdaq: LOXO), with the news sending the latter’s shares up about 63.8% at $229 in pre-market trading today. Lilly was down 2.67% at $111.60 pre-market.

Lilly is offering $235.00 per share in cash, which represents a premium of about 68% to Loxo’s Friday close, or around $8.0 billion. Loxo Oncology is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers.

Just last week, Bristol-Myers Squibb (NYSE: BMY) kicked off the MA& season with a $74 billion  bid for Celgene (Nasdaq: CELG).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology